Evidence map›Paper›PMID 37511107›Full record

ArticleInternational journal of molecular sciences2023

Drug-Inducible Gene Therapy Effectively Reduces Spontaneous Seizures in Kindled Rats but Creates Off-Target Side Effects in Inhibitory Neurons.

Kyle A Sullivan, Iuliia Vitko, Kathryn Blair, Ronald P Gaykema, Madison J Failor, Jennifer M San Pietro, Deblina Dey, John M Williamson, Ruth L Stornetta, Jaideep Kapur and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Genetic medicines for epilepsy: unlocking new avenues for seizure control.Frontiers in bioengineering and biotechnology · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Kyle A SullivanDepartment of Pharmacology, University of Virginia, Charlottesville, VA 22980, USA.ORCID 0000-0002-4621-5598
Iuliia VitkoDepartment of Pharmacology, University of Virginia, Charlottesville, VA 22980, USA.
Kathryn BlairDepartment of Pharmacology, University of Virginia, Charlottesville, VA 22980, USA.
Ronald P GaykemaDepartment of Pharmacology, University of Virginia, Charlottesville, VA 22980, USA.
Madison J FailorDepartment of Pharmacology, University of Virginia, Charlottesville, VA 22980, USA.ORCID 0000-0002-6924-6610
Jennifer M San PietroDepartment of Pharmacology, University of Virginia, Charlottesville, VA 22980, USA.ORCID 0009-0002-4717-9450
Deblina DeyDepartment of Pharmacology, University of Virginia, Charlottesville, VA 22980, USA.
John M WilliamsonDepartment of Neurology, University of Virginia, Charlottesville, VA 22980, USA.
Ruth L StornettaDepartment of Pharmacology, University of Virginia, Charlottesville, VA 22980, USA.
Jaideep KapurDepartment of Neurology, University of Virginia, Charlottesville, VA 22980, USA.
Edward Perez-ReyesDepartment of Pharmacology, University of Virginia, Charlottesville, VA 22980, USA.ORCID 0000-0001-6237-3863
University of Virginia · USOak Ridge National Laboratory · US

Funding

TREATMENT OF STATUS EPILEPTICUSR01NS040337 · NINDS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI KAPUR, JAIDEEP · 2000 to 2021
$5.0M
Developing a drug-inducible gene therapy for temporal lobe epilepsyR01NS097726 · NINDS · UNIVERSITY OF VIRGINIA · PI PEREZ-REYES, EDWARD · 2016 to 2019
$1.4M
Developing a drug-inducible gene therapy for temporal lobe epilepsyR56NS097726 · NINDS · UNIVERSITY OF VIRGINIA · PI PEREZ-REYES, EDWARD · 2023 to 2023
$531k
NINDS NIH HHS NS040337NINDS NIH HHS NS097726NINDS NIH HHS R01 NS040337NINDS NIH HHS R01 NS097726NINDS NIH HHS R56 NS097726
6 · The paper itself

Abstract

Over a third of patients with temporal lobe epilepsy (TLE) are not effectively treated with current anti-seizure drugs, spurring the development of gene therapies. The injection of adeno-associated viral vectors (AAV) into the brain has been shown to be a safe and viable approach. However, to date, AAV expression of therapeutic genes has not been regulated. Moreover, a common property of antiepileptic drugs is a narrow therapeutic window between seizure control and side effects. Therefore, a long-term goal is to develop drug-inducible gene therapies that can be regulated by clinically relevant drugs. In this study, a first-generation doxycycline-regulated gene therapy that delivered an engineered version of the leak potassium channel

Indexed as

Drug-Related Side Effects and Adverse ReactionsEpilepsyEpilepsy, Temporal LobeAnimalsDisease Models, AnimalDoxycyclineGenetic TherapyHippocampusMaleNeuronsRatsDoxycyclineadeno-associated virus (AAV)drug-inducibleelectroencephalogram (EEG)gene therapyspontaneous limbic seizurestemporal lobe epilepsy

Identifiers

PMID37511107
PMCPMC10379297
OpenAlexW4384203198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.